Yüklüyor......
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-...
Kaydedildi:
| Yayımlandı: | J Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Clinical Oncology
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7213585/ https://ncbi.nlm.nih.gov/pubmed/32109194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02250 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|